each of the 36 normalized data sets. Before analysis, gene expression levels were standardized 1 3 8 within each data set using the PAM50 luminal A population as reference. This allowed to 1 3 9 exclude biases due to laboratory-specific variations and to population heterogeneity and to 1 4 0 make data comparable across all sets. PRICKLE1 and ECT2 upregulation in a tumor was 1 4 1 defined by an expression level above median expression the other cases being defined as 1 4 2 downregulation. GEF/GAP activity was based on metagene approach and computed on the 1 4 3 mean of the 10 related genes standardized. GEF/GAP activity "up" was defined by a 1 4 4 metagene score value above the global median of the metagene whereas other cases were 1 4 5 defined as "down". Correlations between tumor classes and clinicopathological variables were analyzed using the 1 4 9 one-way analysis of variance (ANOVA) or the Fisher's exact test when appropriate. Synthetic capped mRFP mRNA was produced using Ambion mMESSAGE mMACHINE Kit. pCS2-mRFP was linearized with NotI and mRNA was synthesized with Sp6 polymerase. Morpholino antisense oligonucleotides (MO) were obtained from Genetools®, and the 1 7 5 sequences were the following: Prickle1 (Pk1) 5'-CCTTCTGATCCATTTCCAAAGGCAT-3' 1 7 6 25 ; ECT2 5'-TACTGGGAGAGCCATGTTTGATTT-3'. Embryos at 2-cell stage were 1 7 7 injected in each blastomere with various doses of MOs. Embryos were cultured in modified 1 7 8
Barth's solution until stage 28, when they were photographed. We and others have shown that PRICKLE1 contribute to cancer cell dissemination in various 1 8 4 cancers 2, [9] [10] [11] . To investigate the molecular mechanisms underlying the role of PRICKLE1 in 1 8 5 tumorigenicity, and notably cell motility and dissemination, we generated a stable cell line identify protein complexes associated to PRICKLE1 in these cells, we performed anti-GFP 1 8 8 immunoprecipitation followed by mass spectrometry analysis. We identified previously 1 8 9
known PRICKLE1 interactors such as VANGL1, MINK1, RICTOR, LL5β, PLK1, and 1 9 0 USP9x, validating our approach (Fig. 1A) . Cell migration is a complex and dynamic process 1 9 1 that involves continuous remodeling of the cellular architecture and relies on spatiotemporal 1 9 2 modulation of signaling networks including Rho-family GTPases. Our attention was attracted interesting drug targets to prevent cancer dissemination. Based on our generated proteomic data describing the protein complex associated to 1 9 9 PRICKLE1, we focused our attention on the 10 regulators of small G-proteins (i.e. Rho-GEF 2 0 0 and Rho-GAP) identified, including ARHGAP21, ARGHAP22, ARHGAP23, ARHGEF2, 2 0 1 ARHGEF40, BCR, ECT2, IQGAP3, MYO9B and STARD13. We assessed the mRNA 2 0 2 expression level of the corresponding genes in a retrospective series of 8,982 clinically 2 0 3 annotated patients with invasive primary breast cancer gathered from several public data 2 0 4 bases (Table S1). Within these 10 genes, ECT2, IQGAP3 and MYO9B were the most 2 0 5 overexpressed in tumors as compared to normal breast ( Fig. 2A) , whereas ARHGEF40 and 2 0 6 STARD13 showed the lowest expression levels. We built a metagene including these 10 genes 2 0 7 and compared its expression level in three molecular subtypes of breast cancer (RH+/HER2-, 2 0 8 HER2+, and TN). The metagene was significantly up-regulated in the TN subtype 2 0 9 comparatively to the two others subtypes (p<1.0 x 10 -250 , Anova) ( Fig. 2B) .
We then searched for correlations between the GAP-GEF metagene expression (as binary the 5-year MFS was 77% (95 Cl, 66-90) in the "metagene-down" group versus 60% (95Cl, 2 2 2 54-66) in the "metagene-up" group (p=0.029, log-rank test; Fig. 2E ). Cooperation between PRICKLE1 and ECT2 as poor-prognosis marker in TNBC 2 2 5
We have previously shown that PRICKLE1 upregulation is associated with poor MFS in basal 2 2 6 breast cancer 2 , a molecular subtype mainly composed of TNBC. In the present series of 2 2 7 TNBC, we confirmed that PRICKLE1 upregulation was associated with shorter metastasis PRICKLE1-down group and the PRICKLE1-up group respectively (p=0.0147, log-rank test) 2 3 0 ( Fig. 2F) . Since PRICKLE1 and the 10 genes of the metagene interact together, we searched 2 3 1
for an eventual cooperation of their association in prognostic term. First, we analyzed the respectively, log-rank test; Fig. 2G ). This data suggest that metagene expression and complementarity between the two prognostic variables was tested in the TN patients using the 2 4 0 likelihood ratio (LR) test. As shown in Table 2A , the metagene tended to add prognostic 2 4 1 information to that provided by PRICKLE1 expression (LR-ΔX2=2.75, p=0.097).
4 2
Second, because ECT2 was one of the most prominent hit identified by mass spectrometry 2 4 3 analysis ( Fig. 1B) and the gene most overexpressed in TNBCs among members of the 2 4 4 metagene ( Fig. 2A) , we investigated whether ECT2 expression alone (without the nine other on the public XenBase repository 29 (data not shown). We noticed a sharp peak of zygotic ect2 2 9 9 expression at stage 9, which decreases abruptly at stage 10, just before gastrulation and CE 3 0 0 movements take place. Zygotic prickle1 expression also begins to increase at stage 9, reaching 3 0 1 a maximum at stage 12 (mid gastrula), and gradually decreasing until the end of neurulation.
3 0 2
We next performed in situ hybridization and detected expression of ect2 RNA in the animal 3 0 3
hemisphere up until stage 9 ( Fig. 4A) . Thus, ect2 transcription appears to terminate when 3 0 4 prickle1 transcription starts. However, inspection of genome-wide proteomic data 30 indicated 3 0 5
that Ect2 protein levels were maintained during gastrulation, suggesting that Ect2 could We and others have demonstrated the prominent role of PRICKLE1 during cancer 3 2 1 progression 2, 9-11 . In this study, we identified the protein complex associated to PRICKLE1 3 2 2
and we aimed to evaluate the impact of PRICKLE1 and its associated protein complex in cancer cell dissemination has been well characterized [31] [32] [33] . Exploiting our transcriptomic 3 2 7
breast cancer database, we showed that this subset of genes is up-regulated in TNBC. Among therapy is currently available due to a lack of specific targets 1 . Here, we show that PRICKLE1 3 3 7
is overexpressed in TNBC and is a poor-prognosis marker. PRICKLE1 is a protein highly ligase, which allows its rapid degradation 34 . PRICKLE1 is also protected from degradation by shows that PRICKLE1 is a pivotal protein in cancer cell dissemination and a candidate for setting up novel therapeutic strategies. During developmental processes and cancer progression, PRICKLE1 is required for oriented 3 4 8 cell migration 2, 9, 11, 37 . At the molecular level, we and others have shown that PRICKLE1 3 4 9
contributes to localize VANGL at the plasma membrane 8, 12 , LL5β at the +ends of the 3 5 0 microtubules 11 , and to restrict localization of the Rho-GAP at the edge of the migrating cancer interacting partners allows the cells to coordinate cellular movements to create a cellular 3 5 6
imbalance and promote directed cell migration. Here we showed that PRICKLE1 also 3 5 7
contribute to regulate the activity of ECT2, a GEF for Rac1, which is essential for cell 3 5 8 motility.
3 5 9
ECT2 is a Rho-GEF controlling Rac1 activity 13 . Although ECT2 has been extensively studied 3 6 0 for its role in the nucleus and during cytokinesis, reports have shown that ECT2 can also be 3 6 1 localized in the cytoplasm of cancerous cells 16 . We observed that ECT2 is localized in actin- to an increase of Rac activity, and that PRICKLE1 overexpression leads to a decrease of this Our data also identified a role for the PET domain of PRICKLE1, as ECT2 is to date the only domain. In open conformation, the PET domain is unmasked, thus activating PRICKLE1. We 3 7 4
can speculate that the interaction between PRICKLE1 and ECT2 can be modulated by 3 7 5
switching between these two conformations providing a still uncharacterized molecular 3 7 6 mechanism of PRICKLE1 activation. Finally, our study identified that ECT2 acts during Xenopus embryonic development. Prickle1 has been extensively characterized for its contribution during convergent-extension 6, 7 3 7 9
movements and has been shown to be asymmetrically distributed within cells in order to 3 8 0 organize their movement 39, 40 . A previous study indicated that Prickle1 mRNA accumulates 3 8 1 within the blastopore lip from the onset of gastrulation 41 . Here, we showed that ect2 mRNA 3 8 2
and presumably Ect2 protein are expressed prior to and in a broader pattern than Prickle1 41 .
8 3
Knockdown experiments strongly suggest that Prickle1 and Ect2 act together to allow CE: convergent-extension movements. The mass spectrometry proteomics data, including search results, will be deposited to the The authors declare no potential conflicts of interest. Universitaire de France. for poor overall survival and recurrence-free survival in non-small cell lung adenocarcinoma. with ECT2. HEK293T cells were co-transfected with the indicated form of PRICKLE1 (see on the left for topology details) and Cherry-ECT2. After FLAG immunopurification, presence form of PRICKLE1 did not modify the gain of function observed by ECT2 overexpression. Ratio Rac1-GTP/Rac1 total 1 1.6 0.6 1.8
